Lowering cholesterol is a key component in the prevention and management of heart disease. Earlier preclinical “in vitro” studies gave Samaritan reason to believe its proprietary peptide SP-1000
The company also recently announced similar approval from the FDA for a similar trial in the US In the trial, patients will undergo a closing of a small
The patients being enrolled in the trial have disease which has begun to progress following at least two prior therapeutic campaigns, either conventional or experimental. Cell-based studies have
The extra six months of exclusivity was granted after Cephalon met the terms of a written request to provide data from clinical studies examining the effect of Provigil
BG Medicine (BGM) will apply their proprietary, integrated systems approach based on proteomics, metabolomics and computational analyses to describe the molecular effects of selected lipid lowering agents on
The collaboration is focused on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia (CML). The new agreement will see SGX
In response to news of the allegation, Schering released a statement which affirmed the company’s belief that Yaz does not infringe on the patent, and that the launch
The 80-patient, multi-center trial will be compared to an historical control group of 80 patients, with survival at day 100 as the primary endpoint. Severe veno-occlusive disease (VOD)
Operating expenses decreased to $10.6 million for the first quarter of 2009 from $12.0 million for the first quarter of 2008, primarily as a result of a strategic
The FDA approved the start of a clinical trial to evaluate the safety and feasibility of the treatment. The trial is expected to begin sometime this spring and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.